Completed
Efficacy and Safety of 80mg Osimertinib in Patients With Non-small Cell Lung Cancer(NSCLC)
NCT04563871
- Conditions
- Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
- Locations
-
- ChungBuk National University Hospital Cheonju, South Korea
- National Cancer Center Goyang, South Korea
- Seoul National University Bundang Hospital Seongnam, South Korea
- Samsung Medical Center Seoul, South Korea